Intranasal drug delivery is clearly a hot topic in brain research
As patients lose substantial weight, their metabolic demands change, potentially altering the dose of levothyroxine needed to maintain euthyroid status
Providers increasingly encounter patients Read More Protecting Muscle While Treating Obesity: New Protein Targets for Older Adults on GLP-1s Jun 16, 2026 Articles, Diet and Nutrition, Exercise, Geriatric Medicine, GLP- 1 Agonist Therapy Center, GLP-1 Agonist Therapy Center, Obesity, Obesity 1,660 views The rise of highly effective GLP-1 receptor agonists and dual incretin therapies has transformed obesity treatment
They hypothesized that delivering tofogliflozin intracerebroventricularly (ICV) could stimulate food intake by acting directly on the CNS, whereas intraperitoneal administration showed no such effects
The products offered by Incretix Labs are not intended to diagnose, treat, cure, or prevent any disease
Abstract A 78-year-old man with dementia experienced waxing and waning of symptoms with changes in altitude as he traveled from his home in the Rocky Mountains to lower elevations and back
